Balyasny Asset Management’s Tenax Therapeutics TENX Stock Holding History

Balyasny Asset Management’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.82M	Buy	+194,000	New	+$2.48M	﹤0.01%	1655

Other funds holding TENX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Balyasny Asset Management's TENX Position: Q2 2026 in Review

Balyasny Asset Management sold out of Tenax Therapeutics (TENX) in Q2 2026, closing a stake of 194,616 shares — an estimated $2.49M sold.

Balyasny Asset Management first reported a position in TENX in Q3 2022 and held it in 2 quarters. The position peaked at $3.11M in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

Balyasny Asset Management reported no remaining Tenax Therapeutics position as of Q2 2026 after selling out during the quarter.
Balyasny Asset Management sold 194,616 Tenax Therapeutics shares in Q2 2026, an estimated $2.49M.
Balyasny Asset Management first reported a position in Tenax Therapeutics in Q3 2022 and held it in 2 quarters.
Balyasny Asset Management's Tenax Therapeutics position peaked at $3.11M in Q1 2026.
111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.